| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma, Large-Cell, Follicular | |||||
| Lymphoma, Follicular | |||||
| Lymphoma, Non-Hodgkin | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma | |||||
| Lymphoma, Large B-Cell, Diffuse | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoma, B-Cell | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| Ibritumomab Tiuxetan | |||||
| Iodine I 131 Tositumomab | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Antibodies, Monoclonal | |||||
| Iodine | |||||
| Iodine-131 anti-B1 antibody | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Anti-Infective Agents, Local | |||||
| Antineoplastic Agents | |||||
| Growth Substances | |||||
| Immunologic Factors | |||||
| Micronutrients | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| Trace Elements | |||||
| 7 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||
|
